Priority Research Area Infections

Cellular Microbiology

Mission   Projects   Funding   Techniques   Publications    Staff


  • NAREB EU FP7 Nanotherapeutics for Antibiotic Resistant Emerging Bacterial pathogens, -2018
  • Leibniz Research Alliance INFECTIONS'21 - Transmission Control of Infections in the 21st Century (Speaker), -2019
  • SAW Projekt 566 The lung microbiota at the interface between airway epithelium and environment, -2019
  • German Center for Infection Research (DZIF) – Thematical Translational Unit Tuberculosis (TTU-TB) Neutrophil signatures in tuberculosis, -2020
  • BMBF Africa: TB Sequel Comorbidities, risk factors and long-term sequelae defining the individual outcome and public health impact of TB disease, -2020
  • EVOLung Iron metabolism genes in the interaction between microbiota, host and tuberculosis, -2020
  • ANTI-TB Targeted nanocarrier for anti-tuberculosis drug delivery (Speaker), -2020
  • DFG Russia-Germany Correlates of exacerbated and ameliorated pathogenesis in experimental and clinical tuberculosis, -2020
  • DFG International Graduate School 1911 Immunoregulation of Inflammation in Allergy and Infection Project B7 Cross-talk between mycobacteria and neutrophils and its impact on tuberculosis persistence, -2022
  • BMG MetaCorDia: Metagenomik Labor für den Nachweis von Coronaviren in respiratorischen Patientenmaterialien & Strukturierte medizinische Ersteinschätzung (SmE), schnelle Diagnostik im Rahmen eines Corona Virus Ausbruchs und neue antivirale Stoffe am FZB, 1.1.-31.12.2020
  • FLAV4AMR Horizon 2020 Flavodoxin inhibitors to kill resistant bacteria, -2019
  • VITALITY Horizon 2020 (EDCTP) Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunpathology: an individually randomised, double-blinded placebo-controlled trial, -2019
  • ETBRA Horizon 2020 (IMI) : European tuberculosis regimen accelerator, - 2019



  • Alexander Apt, Vladimir Yeremeev, Central Institute for Tuberculosis, Moscow 107564, Russia; Properties on susceptibility and resistance in tuberculosis
  • Claus Feldmann, KIT, Karlsruhe; Lea Ann Dailey, University Halle; Katharina Schwarz, ITEM, Hannover; Robert Gieseler, Rodos Targospheres, Hannover; Klaus-Michael Lehr, HIPS, Saarbrücken; Corvin Nycolat, Scripps, La Jolla, USA: Targeted nanocarrier for anti-TB drug delivery
  • Esther Meyron-Holtz, Technion-Israel Institute of Technology, Haifa, Israel: Iron in tuberculosis
  • John Baines, MPI for Evolutionar Biology, Plön; Ken Bruce, Kings College, London, UK: Pulmonary microbiota in infection and immunity
  • Albert Haas, University of Bonn: Trafficking of intracellular bacteria
  • Albert Sickmann, ISAS, Dortmund; Frank Schmidt, Weill Cornell Medicine Qatar; Moran Benhar, Technion-Israel Institute of Technology, Haifa, Israel: Proteomics of host - pathogen interactions
  • Wolfgang Streit, University Hamburg; Joerg Steinmann, University Essen; Jan Rupp, UzL, Lübeck: Stenotrophomonas maltophilia
  • Gareth Griffiths, Oslo; Rudi Reimer, HPI, Hamburg; Alke Meents, DESY, Hamburg: High resolution imaging of infection
  • Kerstin Schepanski, TROPOS, Leipzig; Gülsah Gabriel, HPI, Hamburg; Anne Paschke, Wolfgang Hein, GIGA, Hamburg: Aerosol transmission of airborne pathogens
  • Thomas von Woedtke, INP, Greifswald: Cold plasma in anti-tuberculosis therapy